1. Home
  2. FMAC vs TTRX Comparison

FMAC vs TTRX Comparison

Compare FMAC & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FMAC

Future Money Acquisition Corporation Ordinary Shares

N/A

Current Price

$9.97

Market Cap

157.5M

Sector

Finance

ML Signal

N/A

Logo Turn Therapeutics Inc.

TTRX

Turn Therapeutics Inc.

HOLD

Current Price

$8.81

Market Cap

174.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FMAC
TTRX
Founded
N/A
2015
Country
United States
United States
Employees
N/A
2
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
157.5M
174.9M
IPO Year
2026
N/A

Fundamental Metrics

Financial Performance
Metric
FMAC
TTRX
Price
$9.97
$8.81
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$8.00
AVG Volume (30 Days)
3.4K
80.0K
Earning Date
N/A
05-31-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.96
$2.57
52 Week High
$10.02
$11.69

Technical Indicators

Market Signals
Indicator
FMAC
TTRX
Relative Strength Index (RSI) 46.43 70.27
Support Level N/A $4.40
Resistance Level N/A N/A
Average True Range (ATR) 0.01 0.94
MACD -0.00 0.24
Stochastic Oscillator 28.57 54.29

Price Performance

Historical Comparison
FMAC
TTRX

About FMAC Future Money Acquisition Corporation Ordinary Shares

Future Money Acquisition Corp is a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities.

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

Share on Social Networks: